The DOI matches its Crossref record; 171 of the 179 references it cites were found in a registry or an index.
Advances in the early diagnosis of hepatocellular carcinoma
Open accessAbstract
Hepatocellular carcinoma (HCC) is one of the most prevalent cancers globally. In contrast to the declining death rates observed for all other common cancers such as breast, lung, and prostate cancers, the death rates for HCC continue to increase by ~2-3% per year because HCC is frequently diagnosed late and there is no curative therapy for an advanced HCC. The early diagnosis of HCC is truly a big challenge. Over the past years, the early diagnosis of HCC has relied on surveillance with ultrasonography (US) and serological assessments of alpha-fetoprotein (AFP). However, the specificity and sensitivity of US/AFP is not satisfactory enough to detect early onset HCC. Recent technological advancements offer hope for early HCC diagnosis. Herein, we review the progress made in HCC diagnostics, with a focus on emerging imaging techniques and biomarkers for early disease diagnosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Without definitive tests, healthcare providers often depend on clinical judgment and broader testing approaches, sometimes resulting in diagnostic errors.”
From Toward Safer Diagnoses: A SEIPS-Based Narrative Review of Diagnostic Errors (2026) · cites this paper as [187]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“First, there is a lack of appropriate or specific diagnostic tests for certain conditions or diseases, especially in their early stages [185,186,187].”
From Toward Safer Diagnoses: A SEIPS-Based Narrative Review of Diagnostic Errors (2026) · cites this paper as [187]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Xu, W., Guo, B.-L., Han, Y.-G., Shi, L., & Ma, W. (2014) · Tumor Biology · doi:10.1007/s13277-014-2506-8 · Cited by 34
RetractedEASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,135
Circulating microRNAs as stable blood-based markers for cancer detection
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., Allen, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804549105 · Cited by 7,969
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
AASLD guidelines for the treatment of hepatocellular carcinoma
Heimbach, J. K., Kulik, L., Finn, R. S., Sirlin, C. B., Abecassis, M. M., Roberts, L. R., Zhu, A. X., Murad, M. H., & Marrero, J. A. (2017) · Hepatology · doi:10.1002/hep.29086 · Cited by 4,107
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A. A., Wong, F., Mattox, A., et al. (2018) · Science · doi:10.1126/science.aar3247 · Cited by 2,783
Omata, M., Cheng, A., Kokudo, N., Kudo, M., Lee, J. M., Jia, J., Tateishi, R., Han, K., Chawla, Y. K., Shiina, S., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9799-9 · Cited by 2,219
Tzartzeva, K., Obi, J., Rich, N. E., Parikh, N. D., Marrero, J. A., Yopp, A., Waljee, A. K., & Singal, A. G. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.01.064 · Cited by 1,207
Jansson, M., & Lund, A. H. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.006 · Cited by 1,150
Cited by
Sorted by citations
Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implications
Safri, F., Nguyen, R., Zerehpooshnesfchi, S., George, J., & Qiao, L. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00764-w · Cited by 174
Wei, Y., Tang, X., Ren, Y., Yang, Y. S., Song, F., Fu, J., Liu, S., Yu, M., Chen, J., Wang, S., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00801-2 · Cited by 102
Tang, L., Wei, R., Chen, R., Fan, G., Zhou, J., Qi, Z., Wang, K., Wei, Q., Wei, X., & Xu, X. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.07.030 · Cited by 90
Tiliroside targets TBK1 to induce ferroptosis and sensitize hepatocellular carcinoma to sorafenib
Yang, C., Lu, T., Liu, M., Yuan, X., Li, D., Zhang, J., Zhou, L., & Xu, M. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154668 · Cited by 90
Gajos-Michniewicz, A., & Czyz, M. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.050 · Cited by 89
Metadata
- Authors
- Wang, W., & Wei, C.
- Corresponding author
- Wei, Chao
- ORCID
- Venue
- Genes & Diseases
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 7
- Issue
- 3
- Pages
- 308-319
- ISSN
- 2352-3042 (ISSN-L)
- PMC
- PMC7452544
- OpenAlex
- W3003360914
- Cited by
- 492
- References
- 179
- Citations by year
- 2026: 56 · 2025: 107 · 2024: 126 · 2023: 108 · 2022: 74 · 2021: 19 · 2020: 2
- FWCI
- 6.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Genes & Diseases (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
- Keywords
- hepatocellular carcinoma, early diagnosis, alpha-fetoprotein, ultrasonography, cancer surveillance, imaging modalities, biomarkers, sensitivity and specificity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
